Patents Assigned to Therapeutic Technologies Inc.
-
Patent number: 9315827Abstract: A method for constructing a subgroup B recombinant human adenovirus vector Ad11-5EP. The method includes substituting a 365 bp fragment including an enhancer and a promoter of an upstream coding sequence of Ad5 E1A for a corresponding region of a serotype Ad11 of the subgroup B human adenovirus vector by homologous recombination to construct the subgroup B recombinant human adenovirus vector Ad11-5EP. A subgroup B recombinant human adenovirus vector Ad11-5EP constructed by the method and the use thereof for treatment of tumors are also provided.Type: GrantFiled: November 29, 2013Date of Patent: April 19, 2016Assignee: Beijing Bio-Targeting Therapeutics Technology Inc.Inventors: Yaohe Wang, Guozhong Jiang, Hanshi Wong, Fengyu Cao, Nick Lemoine
-
Publication number: 20140088180Abstract: A method for constructing a subgroup B recombinant human adenovirus vector Ad11-5EP. The method includes substituting a 365 bp fragment including an enhancer and a promoter of an upstream coding sequence of Ad5 E1A for a corresponding region of a serotype Ad11 of the subgroup B human adenovirus vector by homologous recombination to construct the subgroup B recombinant human adenovirus vector Ad11-5EP. A subgroup B recombinant human adenovirus vector Ad11-5EP constructed by the method and the use thereof for treatment of tumors are also provided.Type: ApplicationFiled: November 29, 2013Publication date: March 27, 2014Applicant: Beijing Bio-Targeting Therapeutics Technology Inc.Inventors: Yaohe WANG, Guozhong JIANG, Hanshi WONG, Fengyu CAO, Nick LEMOINE
-
Publication number: 20130345295Abstract: An oncolytic adenovirus vector and its potential application in cancer treatment and vaccination. The inventive vector (named Ad-TD-hIL12) is derived from the human adenovirus group C type 5, more particularly including deletion of three adenovirus genes E1A-CR2, E1B19K and E3gp-19K, and a fused cDNA sequence of p35 and p40 subunit of human IL12 placed under the control of the E3gp-19K promoter. The invention also includes a method to construct the triple gene-deleted vector (Ad-TD). The Ad-TD-hIL12 and Ad-TD-shIL12 (with a short p40 sequence of human IL 12) vectors can be used as targeted, genetically engineered agents for treatment of various solid tumors, via not only intratumoral injection, and also in intraperitoneal injection, without causing significant side effects, showing a superior antitumor efficacy and safety.Type: ApplicationFiled: September 2, 2013Publication date: December 26, 2013Applicant: Beijing Bio-Targeting Therapeutics Technology Inc.Inventors: Yaohe WANG, Guozhong JIANG, Pengju WANG, Dongling GAO, Nick LEMOINE
-
Patent number: 6622320Abstract: A toilet seat lift comprising a base having opposite sides, a seat support mounted on the base for pivotal movement about a generally horizontal axis extending side-to-side with respect to the base between a lowered position and a raised position, a seat on the seat support having an opening therein adapted to overlie a toilet, and a power actuator for pivoting the seat support from its lowered position to its raised position.Type: GrantFiled: March 6, 2002Date of Patent: September 23, 2003Assignee: Showme Therapeutic Technologies, Inc.Inventor: Frederick A. Ward
-
Publication number: 20020124308Abstract: A toilet seat lift comprising a base having opposite sides, a seat support mounted on the base for pivotal movement about a generally horizontal axis extending side-to-side with respect to the base between a lowered position and a raised position, a seat on the seat support having an opening therein adapted to overlie a toilet, and a power actuator for pivoting the seat support from its lowered position to its raised position.Type: ApplicationFiled: March 6, 2002Publication date: September 12, 2002Applicant: Showme Therapeutic Technologies, IncInventor: Frederick A. Ward
-
Patent number: 5738113Abstract: A method for the control and reduction of dental caries is provided for individuals who are at risk of dental caries. The method comprising a first step of applying an antimicrobial treatment followed shortly thereafter by a second step of applying a fluoride treatment.A method for the diagnosis, control and reduction of dental caries, the method comprising testing for Streptococcus mutans in an oral cavity of a patient and determining the patient's risk level for developing dental caries, to establish what treatment, if any, the patient requires in accordance with a set of treatment guidelines.Type: GrantFiled: March 12, 1996Date of Patent: April 14, 1998Assignee: Knowell Therapeutic Technologies, Inc.Inventor: John Jude Connelly
-
Patent number: 5048522Abstract: A method and apparatus are provided for electrically stimulating muscle of individuals having little or no nerve damage so the muscle can be power contracted with little pain to the individual. A therapeutic current is applied to the muscle which includes alternating desensitizing and stimulus currents. The desensitizing current is a high frequency, low amplitude current to desensitize the muscle and the stimulus current is a low frequency, high amplitude current to stimulate the muscle. The currents alternate at a point where the amplitude and slope of the two currents are substantially identical to avoid abruptions in the current. An onset failure monitor circuit is also provided to detect an increase in skim/electrode impedance indicative of possible subsequent failure of the skin-electrode connection or electrode failure.Type: GrantFiled: January 2, 1991Date of Patent: September 17, 1991Assignee: Therapeutic Technologies, Inc.Inventor: Steven H. Petrofsky
-
Patent number: 4996987Abstract: A method and apparatus are provided for electrically stimulating muscle of individuals having little or no nerve damage so the muscle can be power contracted with little pain to the individual. A therapeutic current is applied to the muscle which includes alternating desensitizing and stimulus currents. The desensitizing current is a high frequency, low amplitude current to desensitize the muscle and the stimulus current is a low frequency, high amplitude current to stimulate the muscle. The currents alternate at a point where the amplitude and slope of the two currents are substantially identical to avoid abruptions in the current. An onset failure monitor circuit is also provided to detect an increase in skim/electrode impedance indicative of possible subsequent failure of the skin-electrode connection or electrode failure.Type: GrantFiled: April 13, 1990Date of Patent: March 5, 1991Assignee: Therapeutic Technologies Inc.Inventor: Steven H. Petrofsky
-
Patent number: 4976264Abstract: An electrical muscle stimulator is disclosed which provides unloaded isometric exercise of a pair of antagonist muscles associated with a rotatable limb, substantially without creating torque at the rotating joint. Further, a reduced pain stimulus signal is disclosed characterized in that it is continuous, biphasic and camel-back during a fundamental period thereof.Type: GrantFiled: May 10, 1989Date of Patent: December 11, 1990Assignee: Therapeutic Technologies Inc.Inventor: Steven H. Petrofsky